Literature DB >> 31340669

Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura.

Reheman Adili1, Michael Holinstat1,2.   

Abstract

OBJECTIVE: Microvascular thrombosis is the hallmark pathology of thrombotic thrombocytopenic purpura (TTP), a rare life-threatening disease. Neurological dysfunction is present in over 90% of patients with TTP, and TTP can cause long-lasting neurological damage or death. However, the pathophysiology of microvascular thrombosis in the brain is not well studied to date. Here, we investigate the formation and resolution of thrombosis in pial microvessels. Approach and
Results: Using a cranial intravital microscopy in well-established mouse models of congenital TTP induced by infusion of recombinant VWF (von Willebrand factor), we found that soluble VWF, at high concentration, adheres to the endothelium of the vessel wall, self-associates, and initiates platelet adhesion resulting in the formation of pial microvascular thrombosis in ADAMTS13-/- (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) mice. Importantly, VWF-mediated pial microvascular thrombosis occurred without vascular injury to the brain, and thrombi consisted of resting platelets adhered onto ultra-large VWF without fibrin in the brain in rVWF (recombinant VWF) challenged ADAMTS13-/- mice. Prophylactic treatment with recombinant ADAMTS13 (BAX930) effectively prevented the onset of the VWF-mediated microvascular thrombosis and therapeutic treatment with BAX930 acutely resolved the preexisting or growing thrombi in the brain of ADAMTS13-/- mice after rVWF challenge. The absence of platelet activation and fibrin formation within VWF-mediated thrombi and efficacy of BAX930 was confirmed with an endothelial-driven VWF-mediated microvascular thrombosis model in mice.
CONCLUSIONS: Our results provide important insight into the initiation and development of microvascular thrombi in mouse models that mimics TTP and indicate that rADAMTS13 could be an effective interventional therapy for microvascular thrombosis, the hallmark pathology in TTP.

Entities:  

Keywords:  blood platelets; fibrin; platelet aggregation; thrombosis; von Willebrand factor

Mesh:

Substances:

Year:  2019        PMID: 31340669      PMCID: PMC6709991          DOI: 10.1161/ATVBAHA.119.312848

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  41 in total

1.  Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.

Authors:  H Ni; C V Denis; S Subbarao; J L Degen; T N Sato; R O Hynes; D D Wagner
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

3.  Functional self-association of von Willebrand factor during platelet adhesion under flow.

Authors:  Brian Savage; Jan J Sixma; Zaverio M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

4.  Thrombotic thrombocytopenic purpura: MRI demonstration of persistent small cerebral infarcts after clinical recovery.

Authors:  O Gruber; L Wittig; C J Wiggins; D Y von Cramon
Journal:  Neuroradiology       Date:  2000-08       Impact factor: 2.804

5.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

6.  Thrombotic thrombocytopenic purpura: prospective neurologic, neuroimaging and neurophysiologic evaluation.

Authors:  G Meloni; A Proia; G Antonini; C De Lena; V Guerrisi; S Capria; S M Trisolini; G Ferrazza; G Sideri; F Mandelli
Journal:  Haematologica       Date:  2001-11       Impact factor: 9.941

Review 7.  Recent advances in thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler; Joel L Moake; Toshiyuki Miyata; James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

8.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

Review 9.  Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-30       Impact factor: 8.311

Review 10.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  J Mol Med (Berl)       Date:  2002-09-05       Impact factor: 4.599

View more
  3 in total

Review 1.  Recent Insights Into the Regulation of Coagulation and Thrombosis.

Authors:  Xian Li; Martha M S Sim; Jeremy P Wood
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-22       Impact factor: 8.311

2.  [Recurrent thrombocytopenia with hemolytic anemia in a boy aged 3 years].

Authors:  Min-Hui Zeng; Xiang-Ling He; Xin Tian; Yu-Hui Huang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-05

Review 3.  Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?

Authors:  Dafna J Groeneveld; Lauren G Poole; James P Luyendyk
Journal:  J Thromb Haemost       Date:  2021-05-03       Impact factor: 16.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.